Fetal nucleated cells in the maternal circulation constitute a potential source of cells for the non-invasive prenatal diagnosis of fetal genetic abnormalities. We have investigated the use of the Magnetic Activated Cell Sorter (MACS) for enriching fetal nucleated erythrocytes. Mouse monoclonal antibodies specific for CD45 and CD32 were used to deplete leucocytes from maternal blood using MACS sorting, thus enriching for fetal nucleated erythrocytes which do not express either of these antigens. However, significant maternal contamination was present even after MACS enrichment preventing the accurate analysis of fetal cells by interphase fluorescence in situ hybridisation (FISH). To overcome this problem, we used simultaneous immunophenotyping of cells with the mouse antifetal haemoglobin antibody, UCHy, combined with FISH analysis using chromosome X and Y specific DNA probes. This approach enables selective FISH analysis of fetal cells within an excess of maternal cells. Furthermore, we have confirmed the potential of the method for clinical practice by a pilot prospective study of fetal sex in women referred for amniocentesis between 13 and 17 weeks of gestation.
Abstract
Fetal nucleated cells in the maternal circulation constitute a potential source of cells for the non-invasive prenatal diagnosis of fetal genetic abnormalities. We have investigated the use of the Magnetic Activated Cell Sorter (MACS) for enriching fetal nucleated erythrocytes. Mouse monoclonal antibodies specific for CD45 and CD32 were used to deplete leucocytes from maternal blood using MACS sorting, thus enriching for fetal nucleated erythrocytes which do not express either of these antigens. However, significant maternal contamination was present even after MACS enrichment preventing the accurate analysis of fetal cells by interphase fluorescence in situ hybridisation (FISH). To overcome this problem, we used simultaneous immunophenotyping of cells with the mouse antifetal haemoglobin antibody, UCHy, combined with FISH analysis using chromosome X and Y specific DNA probes. This approach enables selective FISH analysis of fetal cells within an excess of maternal cells. Furthermore, we have confirmed the potential of the method for clinical practice by a pilot prospective study of fetal sex in women referred for amniocentesis between 13 and 17 weeks of gestation.
(J Med Genzet 1993;30:1051- 6) There have been a number of reports showing the presence of nucleated cells of fetal origin in the maternal circulation during pregnancy. Although these cells are rare, they have generated great interest as a potential source of fetal cells for the non-invasive prenatal diagnosis of genetic abnormalities. Various fetal cell types (trophoblasts, erythrocytes, and leucocytes) cross the placenta and circulate within maternal blood.'2 The cell type which appears to offer the most potential for prenatal diagnosis is the fetal nucleated erythrocyte as fetal lymphocytes may persist from previous pregnancies and syncytiotrophoblast may not reflect the fetal genome. Fetal nucleated erythrocytes have been isolated from maternal blood during pregnancy using monoclonal antibodies and flow sorting 8 and have been detected as early as 11 weeks of gestational age.367
Analysis of fetal nucleated erythrocytes sorted from maternal blood generally has been restricted to the determination of fetal sex by use of the polymerase chain reaction (PCR) with Y specific primers. More recently, fluorescence in situ hybridisation (FISH) has been used for the detection of aneuploidies in flow sorted fetal cells.358 Trisomy 21 was found in this way in blood samples taken from pregnant women either after or, in one case, before chorionic villus sampling (CVS). However, the main problem with this approach is that the majority of the nucleated cells analysed are of maternal origin even after FACS sorting. Therefore, the diagnosis of fetal aneuploidy, which relies on the detection of abnormal numbers of hybridisation signals, is insensitive in these samples owing to the high level of normal maternal cell contamination and the inability to distinguish fetal cells from maternal cells.
We have investigated the use of the Magnetic Activated Cell Sorter (MACS) for enriching fetal nucleated erythrocytes. Leucocyte common antigen, CD45, is present on the cell surface of all mature human leucocytes and CD32 is present on mature granulocytes. Neither of these antigens appears to be expressed on nucleated erythrocytes. We have used mouse monoclonal antibodies to these antigens and MACS sorting to enrich fetal nucleated erythrocytes from maternal leucocytes by negative selection. The isolated cells have then been analysed by using fluorescence immunophenotyping with an antibody specific for fetal haemoglobin (Hb F) simultaneously with FISH. In this way, fetal cells are identified by the presence of Hb F and sexed using X and Y specific probes hybridised to these nuclei. The ability to focus the diagnostic procedure exclusively on cells of fetal origin represents a substantial advance on previous techniques.
Materials and methods

BLOOD SAMPLES AND CELL PREPARATION
Peripheral blood (20 ml) was drawn into heparinised tubes from pregnant women before amniocentesis at between 13 and 17 weeks of gestational age. The blood was diluted 1:2 in phosphate buffered saline (PBS).
Step gradients were prepared by pipetting 5 Preparations for microscopy were made using a cytocentrifuge (Shandon Southern, Runcorn, UK) from the cells isolated by MACS from maternal blood and from control samples. Cells from cord blood were used as positive controls and maternal cells before MACS separation were used as negative controls. The slides were air dried overnight, fixed in 2% formaldehyde in PBS at room temperature for 10 
Discussion
It has been shown by others that fetal nucleated erythrocytes can be isolated from maternal blood by FACS sorting using anti-transferrin receptor and anti-glycophorin-A antibodies. '8 However, this procedure is time consuming 
